Targeting specific changes in a cancer-related gene in stomach and esophagus cancer
Official title: Targeting FGFR Alterations in Gastroesophageal Cancer
Funded at Columbia University Health Sciences · NIH-10999105 · Data updated 2026-11-12
This study is looking at new ways to treat stomach and esophagus cancer for patients with certain changes in their FGFR2 gene, by combining regular chemotherapy with special targeted treatments to help improve their chances of recovery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 15, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $716,314 |
| NIH project number | 1R01CA294689-01 |
| Project ID | NIH-10999105 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with gastroesophageal adenocarcinoma who exhibit FGFR2 gene alterations.
✕Less likely to help
Patients without gastroesophageal adenocarcinoma or those whose cancer does not involve FGFR2 alterations may not benefit from this research.
What this research studies
This research focuses on gastroesophageal adenocarcinoma, a type of cancer affecting the stomach and esophagus, particularly in patients with specific alterations in the FGFR2 gene. The study aims to explore new treatment options that combine standard chemotherapy with targeted therapies, including monoclonal antibodies and tyrosine kinase inhibitors, to improve patient outcomes. By investigating the mechanisms of resistance to current treatments, the research seeks to develop innovative combination therapies that may enhance effectiveness against this aggressive cancer. Patients may be involved in clinical trials assessing these new treatment strategies.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with gastroesophageal adenocarcinoma, potentially improving survival rates and quality of life.
How similar studies have gone: Previous clinical trials targeting FGFR2 in gastroesophageal cancer have shown promising results, indicating that this approach has potential based on earlier successes.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Ryeom, Sandra — Columbia University Health Sciences
- Study coordinator: Ryeom, Sandra
Related research
Other NIH-funded projects on the same topics.
-
Targeting FGFR Alterations in Gastroesophageal Cancer
A study aiming to improve treatment for stomach and esophagus cancers by targeting FGFR2 alterations, including combinations with antibody therapies.
-
FGFR-targeted treatments for stomach and esophagus cancer
Developing new drug combinations that target FGFR2 changes for people with gastroesophageal (stomach and esophagus) cancer.
-
Combining immunotherapy to improve treatment for metastatic gastroesophageal cancer
This study is exploring a new way to treat advanced stomach and esophagus cancer by using a mix of immune therapies to help your body fight the cancer better, and it's designed for patients looking for improved treatment options.
-
MGC030 in adults with advanced solid tumors
This trial tests MGC030 in adults with advanced urothelial, gastric/GEJ, esophageal, colorectal, gastric, pancreatic, or GEJ cancers to see if it is safe and whether it can shrink tumors or stop growth.
-
First-in-human dose study of DA-3501 for CLDN18.2-positive stomach, GEJ cancer, and pancreatic cancer
A first-in-human study tests DA-3501 in adults with CLDN18.2-positive advanced stomach/GEJ cancer or pancreatic cancer to find a safe, effective dose.
-
Collecting blood and leftover tumor tissue to test molecular residual disease (MRD) detection
This project will test whether blood and leftover tumor tissue from adults with certain solid tumors can be used with Natera's MRD blood tests to find tiny amounts of cancer (ctDNA) after treatment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.